<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077558</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000352322, J0357</org_study_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0357</secondary_id>
    <secondary_id>NCI-6255</secondary_id>
    <nct_id>NCT00077558</nct_id>
  </id_info>
  <brief_title>3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase I Trial Of Sequential Administration Of Triapine (3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone) Followed By Fludarabine In Adults With Relapsed And Refractory Leukemias And Myelodysplasias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop&#xD;
      cancer cells from dividing so they stop growing or die. 3-AP may help fludarabine kill more&#xD;
      cancer cells by making them more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of fludarabine when&#xD;
      given together with 3-AP in treating patients with relapsed or refractory acute leukemia,&#xD;
      chronic leukemia, or high-risk myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility and tolerability of 3-AP (Triapine^® ) followed by fludarabine&#xD;
           in patients with relapsed or refractory acute or chronic leukemia or high-risk&#xD;
           myelodysplastic syndromes.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of fludarabine. Patients are stratified&#xD;
      according to disease (acute leukemias and myelodysplastic syndromes [MDS] vs chronic&#xD;
      lymphocytic leukemia and prolymphocytic leukemia). Patients are assigned to 1 of 2 treatment&#xD;
      groups.&#xD;
&#xD;
        -  Group 1 (chronic lymphocytic leukemia or prolymphocytic leukemia): Patients receive 3-AP&#xD;
           (Triapine^®) IV over 4 hours and fludarabine IV over 30 minutes on days 1-5.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of fludarabine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional&#xD;
      patients are treated at that dose level.&#xD;
&#xD;
        -  Group 2 (acute leukemias or MDS): Patients receive 3-AP IV continuously over 24 hours on&#xD;
           day 1. Beginning within 4 hours after completion of 3-AP, patients receive fludarabine&#xD;
           IV over 30 minutes on days 2-6.&#xD;
&#xD;
      In both groups, treatment repeats every 3 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-34 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  High-risk myelodysplastic syndromes (MDS), including refractory anemia with&#xD;
                  excess blasts and chronic myelomonocytic leukemia&#xD;
&#xD;
                    -  International Prognostic Scoring System (IPSS) score at least 1.5 based on&#xD;
                       the following:&#xD;
&#xD;
                         -  More than 10% marrow blasts&#xD;
&#xD;
                         -  Cytopenias in at least 2 lineages&#xD;
&#xD;
                         -  Adverse cytogenetics&#xD;
&#xD;
               -  Acute myeloid leukemia (AML)&#xD;
&#xD;
                    -  All subtypes, including MDS/AML and treatment-related (secondary) AML&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
               -  Acute progranulocytic leukemia&#xD;
&#xD;
                    -  Ineligible for arsenic therapy&#xD;
&#xD;
               -  Chronic myelogenous leukemia&#xD;
&#xD;
                    -  Accelerated phase or blastic crisis&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
               -  Prolymphocytic leukemia&#xD;
&#xD;
          -  Received or ineligible for established curative regimens, including stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  Acute and chronic leukemias must be relapsed and/or refractory with progressive&#xD;
             disease since last therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No history of hemolytic anemia grade 2 or greater&#xD;
&#xD;
          -  No known glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
               -  G6PD screening required for high-risk groups (i.e., patients of African, Asian,&#xD;
                  or Mediterranean origin/ancestry)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2.5 times normal&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
          -  No chronic hepatitis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No active heart disease&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No severe coronary artery disease&#xD;
&#xD;
          -  No arrhythmias (other than atrial flutter or fibrillation) requiring medication&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No dyspnea at rest or with minimal exertion&#xD;
&#xD;
          -  No severe pulmonary disease requiring supplemental oxygen&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No neuropathy grade 2 or greater&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
               -  Infections under active treatment and controlled by antibiotics are allowed&#xD;
&#xD;
          -  No other life-threatening illness&#xD;
&#xD;
          -  No psychiatric illness that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior hematopoietic growth factor (e.g., epoetin alfa,&#xD;
             filgrastim [G-CSF], sargramostim [GM-CSF], interleukin-3, and interleukin-11)&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy (no greater than grade 1 chronic toxic effects)&#xD;
&#xD;
          -  At least 72 hours since prior hydroxyurea&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive cytotoxic agents (6 weeks for mitomycin&#xD;
             or nitrosoureas)&#xD;
&#xD;
          -  No more than 12 prior courses of fludarabine&#xD;
&#xD;
          -  No more than 3 prior cytotoxic chemotherapy regimens&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 1 week since prior non-myelosuppressive treatment&#xD;
&#xD;
          -  No more than 4 prior induction regimens&#xD;
&#xD;
          -  No other concurrent therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith E. Karp, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Group of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342-4777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, Thein M, Sznol M, Low J. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk Res. 2008 Jan;32(1):71-7. Epub 2007 Jul 20.</citation>
    <PMID>17640728</PMID>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2004</study_first_posted>
  <last_update_submitted>March 9, 2010</last_update_submitted>
  <last_update_submitted_qc>March 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2010</last_update_posted>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

